Peptimmune, Inc. Secures $20,400,000 Series C Financing

  • Feed Type
  • Date
    7/15/2005
  • Company Name
    Peptimmune, Inc.
  • Mailing Address
    64 Sidney Street Cambridge, MA 02139
  • Company Description
    Peptimmune is a clinical stage biotechnology company that is utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders.
  • Website
    http://www.peptimmune.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,400,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The proceeds of the financing are being used to advance clinical development of Peptimmune’s autoimmune and metabolic disease programs
  • M&A Terms
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    MPM Capital
  • Venture Investor
    Prism VentureWorks
  • Venture Investor
    Vanguard Ventures
  • Venture Investor
    Hunt Ventures
  • Venture Investor
    Silicon Valley Bank
  • Venture Investor
    Itochu Corporation

By posting a comment, you agree to our terms and conditions.